| 刘凯,李婧.新型降脂药人前蛋白转化酶枯草溶菌素 9抑制剂与动脉粥样硬化性心血管疾病、静脉血栓栓塞疾病关系的研究进展[J].安徽医药,2022,26(11):2141-2144. |
| 新型降脂药人前蛋白转化酶枯草溶菌素 9抑制剂与动脉粥样硬化性心血管疾病、静脉血栓栓塞疾病关系的研究进展 |
| Research progress on the relationship between the new lipid-lowering drug PCSK9 inhibitor and ASCVD and VTE |
| |
| DOI：10.3969/j.issn.1009-6469.2022.11.005 |
| 中文关键词: 降血脂药物 人前蛋白转化酶枯草溶菌素 9 人前蛋白转化酶枯草溶菌素 9抑制剂 低密度脂蛋白胆固醇 脂蛋白(a) 动脉粥样硬化性心血管疾病 静脉血栓栓塞症 |
| 英文关键词: Hypolipidemic agents Human proprotein convertase subtilisin 9 Human proprotein convertase subtilisin 9 inhibi. tor Low-density lipoprotein cholesterol Lipoprotein (a) Atherosclerotic cardiovascular disease Venous thromboembolism |
| 基金项目:湖北省自然科学基金资助项目( 2018CFC817) |
|
| 摘要点击次数: 1541 |
| 全文下载次数: 550 |
| 中文摘要: |
| 随着生活方式的改变，心脑血管疾病逐渐成为全人类死亡的“头号杀手”高于恶性肿瘤、糖尿病等。血脂的升高尤其是低密度脂蛋白胆固醇( LDL-C)的升高与动脉粥样硬化性心血管疾病( ASCVD)的发，生、发展息息相关。现有的专家共识、南提出他汀类药物是降低 LDL-C的一线用药，但仍可能会发生复发性缺血事件。人前蛋白转化酶枯草溶菌素 9(PCSK9)抑制指剂作为一类新型降脂药，有显著降低血 LDL-C水平，同时又可降低脂蛋白( a)的水平，又与 ASCVD与静脉血栓栓塞疾病( VTE)的发病可能相关。本文将系统地阐述新型降脂药 PCSK9抑制剂与 ASCVD、VTE的关系研究进展。 |
| 英文摘要: |
| With changes in lifestyle, cardiovascular and cerebrovascular diseases have gradually become the "no. 1 killer" of all hu.man deaths, higher than malignant tumors and diabetes. The increase in blood lipids, especially the increase in low-density lipoprotein cholesterol (LDL-C) is closely related to the occurrence and development of atherosclerotic cardiovascular disease (ASCVD). Existing ex.pert consensus and guidelines suggest that statins are the first-line drugs for lowering LDL-C, but recurrent ischemic events may still oc. cur. Human proprotein convertase subtilisin 9 (PCSK9) inhibitors, as a new class of lipid-lowering drugs, can significantly reduce blood LDL-C levels and reduce lipoprotein (a) levels and are related to ASCVD and venous thromboembolic disease (VTE). This article system.atically describes the research progress on the relationship between new lipid-lowering drug PCSK9 inhibitors and SCVD and VTE. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
